CRP Cancer Research Results

CRP, C-reactive protein: Click to Expand ⟱
Source:
Type:
C-Reactive Protein (CRP) is a protein produced by the liver in response to inflammation in the body.
C-reactive protein is an acute-phase reactant synthesized by the liver in response to IL-6–driven inflammation.

In oncology, it serves as a host-response biomarker, not a tumor marker.

An elevated CRP integrates multiple cancer-relevant processes:
-Tumor-associated inflammation and necrosis
-Cytokine signaling (especially IL-6)
-Infection or treatment-related tissue injury
-Cachexia and systemic catabolism

Because it aggregates these signals, CRP is a powerful global severity indicator.

Prognosis (Primary Use)
-Higher baseline CRP correlates with shorter overall survival across many cancers.
-Rising CRP often precedes clinical decline.

Treatment Tolerance & Risk
-Elevated CRP predicts poor chemotherapy tolerance, higher complication rates, and inferior immunotherapy outcomes in several settings.


Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

EGF↓, 1,   FGFR1↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   LDH↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↓, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   FasL↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p38↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

miR-21↑, 1,   p‑pRB↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B-II↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PARP↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↑, 1,   CycB/CCNB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 1,   ERK↑, 1,   FGF↓, 1,   IGFBP3↑, 1,   mTOR↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   RAS↓, 1,   Shh↓, 1,   Wnt↓, 1,  

Migration ⓘ

FAK↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   PDGF↓, 1,   TGF-β↓, 1,   TSP-1↑, 1,   uPA↓, 1,   uPAR↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CRP↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   LDH↑, 1,  
Total Targets: 74

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CRP, C-reactive protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:884  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page